The mechanism of action of ritexitinib

Ritlecitinib (Ritlecitinib) is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older. Combination use with other JAK inhibitors, biological immunomodulators, cyclosporine or other potent immunosuppressants is not recommended.

Alopecia areata is an autoimmune disease that causes hair loss primarily on the scalp as well as on the face and other areas. Under normal circumstances, hair follicles are immune-privileged sites characterized by the presence of well-suppressed natural killer cells. However, disruption of this system can lead to loss of immune privilege and cause alopecia areata. Genome-wide association studies have linked overexpression of UL16-binding protein 3 (ULBP3), a protein that binds to natural killer cell receptors, to the pathogenesis of alopecia areata. Overexpression of ULBP3 promotes cytotoxic cluster differentiation 8-positive (CD8+) NK group 2D-positive (NKG2D+) T cells to attack hair follicles, leading to hair follicle dystrophy. CD8+ NKG2D+ T cells promote hair follicle inflammation through the interferon-γ (IFN-γ) and interleukin-15 (IL-15) signaling pathways, thereby activating the Janus kinase (Janus signal transducer and activator of transcription (STAT) molecular pathway. Therefore, JAK inhibitors have been proposed for the treatment of alopecia areata.

Ritexitinib irreversibly inhibits Janus kinase 3 (JAK3) and tyrosine kinases expressed in the hepatocellular carcinoma (TEC) kinase family by blocking the adenosine triphosphate (ATP) binding site. In vitro, ritexitinib inhibits cytokine-induced STAT phosphorylation mediated by JAK3-dependent receptors and signaling by immune receptors dependent on members of the TEC kinase family. 5AlthoughJAK inhibitors, such as ritexitinib, may inhibit the inflammatory pathways activated in alopecia areata, their exact mechanism of action has not been fully elucidated.

In addition, the safety of ritexitinib has also been widely recognized. While some patients may experience mild side effects, such as headache, diarrhea, or acne, these symptoms can usually be effectively managed by adjusting the drug dose or combining it with other medications.

Notably, ritixitinib not only excels in the treatment of alopecia areata, but also has the potential to be an effective drug in the treatment of other autoimmune diseases. However, as a prescription drug, it needs to be used under the guidance of a doctor, and the condition must be monitored regularly to ensure treatment effectiveness and patient safety.

Overall, ritexitinib is a new drug with significant efficacy and good safety profile. It provides a new treatment option for patients with alopecia areata, brings hope of hair regeneration, and also brings new possibilities to the field of treatment of autoimmune diseases.